Teos will look to distribute its cash reserves to shareholders, along with proceeds raised from selling pipeline assets.

Spero Therapeutics and partner GSK are stopping a late-stage trial of an experimental oral drug for complicated urinary tract ...

GSK PLC closed 18.99% short of its 52-week high of £17.88, which the company achieved on May 28th.

The U.S. Food and Drug Administration has approved British drugmaker GSK's asthma drug to treat some patients with a chronic ...

GSK and Spero Therapeutics’ Phase III trial of their oral antibiotic for complicated urinary tract infections (cUTI) will end ...

GSK and Spero ended a Phase 3 trial early meeting efficacy goals in cUTIs, positioning its treatment as the first oral ...

GSK’s decision to swoop in and save Spero Therapeutics’ antibiotic three years ago appears to have paid off based on a fresh ...

Spero Therapeutics (SPRO) stock jumps as GSK (GSK) partnered oral UTI treatment, tebipenem HBr, succeeds in a pivotal Phase 3 ...

A month after the FDA lifted its clinical hold on GSK’s vaginal yeast infection drug Brexafemme (ibrexafungerp), the ...

In a second piece of good news in the development of new antimicrobials this week, GSK has said it will file its oral ...

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of ...

GSK Plc halted a trial following positive results for an oral antibiotic to treat complicated urinary tract infections that could replace an intravenous medicine that is typically used.